Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-963-0100
Debt
Current Ratio3.45
Quick Ratio3.45
Price-To-Earnings
Sales & Book Value
Annual Sales$2.44 million
Price / Sales184.39
Price / Cash FlowN/A
Price / Book7.56
Profitability
Net Income$-32,420,000.00
Net MarginsN/A
Return on Assets-71.21%
Miscellaneous
Employees47
OptionableOptionable
Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions
What is Corbus Pharmaceuticals' stock symbol?
Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals' earnings last quarter?
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) issued its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.05. The biopharmaceutical company had revenue of $1.09 million for the quarter, compared to the consensus estimate of $1.66 million. View Corbus Pharmaceuticals' Earnings History.
When is Corbus Pharmaceuticals' next earnings date?
What price target have analysts set for CRBP?
6 brokers have issued 12-month price targets for Corbus Pharmaceuticals' shares. Their predictions range from $22.00 to $38.00. On average, they expect Corbus Pharmaceuticals' share price to reach $26.20 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.
What is the consensus analysts' recommendation for Corbus Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.
Has Corbus Pharmaceuticals been receiving favorable news coverage?
News headlines about CRBP stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of Corbus Pharmaceuticals' key competitors?
Some companies that are related to Corbus Pharmaceuticals include Zogenix (ZGNX), Madrigal Pharmaceuticals (MDGL), PTC Therapeutics (PTCT), Corcept Therapeutics (CORT), Insmed (INSM), Mallinckrodt (MNK), Portola Pharmaceuticals (PTLA), Pacira Pharmaceuticals (PCRX), Prestige Consumer Healthcare (PBH), Cambrex (CBM), Theravance Biopharma (TBPH), Vanda Pharmaceuticals (VNDA), The Medicines (MDCO), Biohaven Pharmaceutical (BHVN) and Aimmune Therapeutics (AIMT).
Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the folowing people:
- Yuval Cohen, Chief Executive Officer & Director
- Mark A. Tepper, President & Chief Scientific Officer
- Sean F. Moran, CFO & Principal Accounting Officer
- Barbara White, Chief Medical Officer
- Robert Discordia, VP-Pharmaceutical Development & Manufacturing
How do I buy shares of Corbus Pharmaceuticals?
Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals' stock price today?
One share of CRBP stock can currently be purchased for approximately $7.86.
How big of a company is Corbus Pharmaceuticals?
Corbus Pharmaceuticals has a market capitalization of $455.04 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.
What is Corbus Pharmaceuticals' official website?
How can I contact Corbus Pharmaceuticals?
Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]
MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
